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Adiponectin deficiency increases leukocyte-
endothelium interactions via upregulation of 
endothelial cell adhesion molecules in vivo
Raogo Ouedraogo,1 Yulan Gong,2 Brett Berzins,2 Xiandong Wu,1 Kalyankar Mahadev,1  
Kelly Hough,1 Lawrence Chan,3 Barry J. Goldstein,1 and Rosario Scalia2
1Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine, and 2Department of Molecular  
Physiology and Biophysics, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.  
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This	study	reports	on	what	we	believe	are	novel	mechanism(s)	of	the	vascular	protective	action	of	adiponectin.	
We	used	intravital	microscopy	to	measure	leukocyte-endothelium	interactions	in	adiponectin-deficient	(Ad–/–)	
mice	and	found	that	adiponectin	deficiency	was	associated	with	a	2-fold	increase	in	leukocyte	rolling	and	a	
5-fold	increase	in	leukocyte	adhesion	in	the	microcirculation.	Measurement	of	endothelial	NO	(eNO)	revealed	
that	adiponectin	deficiency	drastically	reduced	levels	of	eNO	in	the	vascular	wall.	Immunohistochemistry	dem-
onstrated	increased	expression	of	E-selectin	and	VCAM-1	in	the	vascular	endothelium	of	Ad–/–	mice.	Systemic	
administration	of	the	recombinant	globular	adiponectin	domain	(gAd)	to	Ad–/–	mice	significantly	attenuated	
leukocyte-endothelium	interactions	and	adhesion	molecule	expression	in	addition	to	restoring	physiolog-
ic	levels	of	eNO.	Importantly,	prior	administration	of	gAd	also	protected	WT	mice	against	TNF-α–induced	
leukocyte-endothelium	interactions,	indicating	a	pharmacologic	action	of	gAd.	Mechanistically,	blockade	of	
eNOS	with	Nω-nitro-l-arginine	methyl	ester	(l-NAME)	abolished	the	inhibitory	effect	of	gAd	on	leukocyte	
adhesion,	demonstrating	the	obligatory	role	of	eNOS	signaling	in	the	antiinflammatory	action	of	gAd.	We	
believe	this	is	the	first	demonstration	that	gAd	protects	the	vasculature	in	vivo via	increased	NO	bioavailability	
with	suppression	of	leukocyte-endothelium	interactions.	Overall,	we	provide	evidence	that	loss	of	adiponectin	
induces	a	primary	state	of	endothelial	dysfunction	with	increased	leukocyte-endothelium	adhesiveness.
Introduction
Adiponectin is an adipocyte-derived protein with insulin-sensitiz-
ing, antiinflammatory, and antiatherogenic properties, abundantly 
found in the plasma in various oligomeric forms (1, 2). In general, 
decreased plasma levels of adiponectin have been associated with 
obesity, a well-known risk factor for cardiovascular disease (3), 
type 2 diabetes (4), and hypertension (5) although no study to date 
has implicated specific adiponectin isoforms in these conditions. 
Accordingly, plasma adiponectin levels are significantly lower in 
patients with coronary artery disease, further suggesting that physi-
ologic levels of adiponectin are necessary to maintain the normal, 
noninflammatory phenotype of the vascular wall (4, 6). In agree-
ment with these clinical observations, adiponectin-deficient (Ad–/–) 
mice develop inflammatory-type vascular disorders in response to 
mechanical injury. Thus, severe neointimal thickening and increased 
proliferation of vascular smooth muscle cells occur in arteries of 
Ad–/– mice following external cuff injury (7). Notably, restoration 
of physiologic levels of adiponectin by recombinant adenovirus 
transduction in vivo was shown to attenuate neointimal prolifera-
tion in Ad–/– mice by reducing smooth muscle cell proliferation (8).
Recent data have linked the vascular protective role of adipo-
nectin with preservation of endothelial cell function. Reduced 
endothelial NO (eNO) availability at the vascular wall causes 
endothelial dysfunction (9), and the dysfunctional endothelium 
expresses a proinflammatory phenotype characterized by elevated 
expression of atherogenic cell adhesion molecules (CAMs) (10), 
in part due to loss of eNO (11). Upregulation of CAMs at the 
endothelial cell surface initiates pathologic leukocyte–endothelial 
cell interactions (12), which ultimately expose the vascular wall 
and surrounding tissues to the damaging action of activated leuko-
cytes. Ouchi and coworkers (13) showed that endothelium-depen-
dent relaxation is impaired in Ad–/– mice, suggesting that loss of 
adiponectin impairs eNO signaling. In addition, adiponectin has 
been shown to enhance NO production in cultured endothelial 
cells in vitro (14–16). Recent evidence has linked increased leu-
kocyte-endothelium interactions in the microcirculation with 
inflammatory signal activation and the vascular complications 
of diabetes (17), a metabolic condition associated with reduced 
levels of adiponectin (4). Indeed, in vitro studies demonstrate that 
adiponectin exhibits antiinflammatory effects, including the sup-
pression of TNF-α–induced adhesion molecule expression (18).
In the present work, we sought to address the following: (a) 
the impact of adiponectin deficiency on baseline leukocyte–
endothelial cell interactions in the microcirculation in vivo; (b) 
the effect of administration of globular adiponectin domain 
(gAd) on leukocyte-endothelium interactions in Ad–/– mice as 
well as in WT mice exhibiting TNF-α–induced vascular inflam-
mation; and (c) the role of eNO in the vascular protective action 
of adiponectin in vivo. Our results clearly demonstrate that loss 
of adiponectin function induces endothelial dysfunction char-
acterized by loss of eNO and increased leukocyte-endothelium 
Nonstandard	abbreviations	used: Ad–/–, adiponectin-deficient (mouse); Ad+/–, 
adiponectin-hemizygous (mouse); CAM, cell adhesion molecule; eNO, endothelial 
NO; gAd, globular adiponectin domain; K-H, Krebs-Henseleit; l-NAME, Nω-nitro-l-
arginine methyl ester.
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interactions. We also found that administration of gAd effec-
tively preserves endothelial function in both acute inflammation 
and states of chronic adiponectin deficiency.
Results
Adiponectin deficiency increases leukocyte-endothelium interactions. To 
study the effect of adiponectin deficiency on vascular inflamma-
tion, we monitored basal leukocyte-endothelium interactions in 
WT mice, mice completely lacking adiponectin (Ad–/–), and adipo-
nectin-hemizygous (Ad+/–) mice. WT mice had endogenous total 
adiponectin plasma levels in the range of 11 ± 0.8 μg/ml. In con-
trast, levels of total adiponectin were virtually undetectable in the 
serum of Ad–/– mice (average values were 0.1 ± 0.1 μg/ml; P < 0.001 
versus WT), confirming the functional phenotype of the adipo-
nectin knockout mouse model used in our study (19). Following 
administration of 25 μg gAd s.c. to Ad–/– mice, serum gAd levels 
increased to 0.55 ± 0.1 μg/ml (n = 2). Ad+/– mice obtained by exten-
sive (>15 generations) backcrossing of Ad–/– mice with WT C57BL/6J 
mice showed a 58% reduction in total plasma adiponectin lev-
els compared with WT mice (average values were 4.6 ± 1 μg/ml; 
P < 0.01 versus WT and Ad–/–). Thus, unpairing of the adiponectin 
gene induces the expression of intermediate phenotypes.
Intravital microscopy studies revealed a very low number of 
rolling leukocytes in peri-intestinal venules of control WT mice 
(Figure 1A). In contrast, Ad–/– mice exhibited a 2-fold increase 
in the number of rolling leukocytes. Leukocyte rolling was 
also increased in Ad+/– mice although to a lower degree than in 
Ad–/– mice (Figure 1A). Moreover, leukocyte rolling velocities 
(31.04 ± 1.50 μm/s in WT mouse venules) were reduced in Ad+/– 
and Ad–/– mice, with the slowest leukocyte rolling velocity detect-
ed in Ad–/– mice (19.40 ± 0.44 μm/s; P < 0.01 versus WT; Figure 2). 
These data demonstrate that reduced levels of serum adiponectin 
are associated with progressively increased leukocyte-endothelium 
interactions in the microcirculation.
A very low number of leukocytes were also found to adhere to the 
vascular endothelium of WT mice (Figure 1B). Conversely, leuko-
cyte adhesion increased 5-fold and 2.5-fold in Ad–/– mice and Ad+/– 
mice (P < 0.01 and P < 0.05 versus WT, respectively). As shown in 
Table 1, no physiologically meaningful differences in body weight, 
blood glucose levels, mean arterial blood pressure, venular diam-
eters, or total leukocyte counts were observed among the groups 
of mice studied. However, leukocyte blood counts increased after 
injection of the E-selectin blocking antibody 9A9, probably due to 
mobilization of adhering leukocytes to the circulating blood com-
partment (20). Thus, under our experimental conditions, changes 
in leukocyte-endothelium interactions were not due to alterations 
in glucose metabolism, circulating leukocyte numbers, systemic 
hemodynamic variables, or local rheologic factors.
Parallel experiments in isolated mouse aorta ex vivo demon-
strated that the aortic endothelium of Ad–/– mice has significantly 
increased adhesiveness to formyl-Met-Leu-Phe–activated human 
monocytic cells. For these studies, 12 aortic segments from 3 mice 
were studied in each group. The average number of monocytic 
cells adhering to control aorta from WT mice was only 4.3 ± 0.4 
cells per microscopic field. In contrast, a total of 10.1 ± 0.6 and 
7.7 ± 0.7 cells per microscopic field adhered to aortic segments 
isolated from Ad–/– and Ad+/– mice, respectively (P < 0.01 versus 
WT aorta). These data are in agreement with data on leukocyte 
adhesion obtained by intravital microscopy, and they demonstrate 
that in the setting of declining levels of adiponectin, the vascular 
endothelium develops a proadhesive phenotype widely affecting 
large conduit vessels as well as the microcirculation.
gAd treatment attenuates leukocyte-endothelium interactions. To ascer-
tain whether restoration of adiponectin signaling could reverse the 
abnormalities in leukocyte-endothelium interactions observed in 
Ad–/– mice, we treated Ad–/– mice with human recombinant gAd 
for a period of 10 days, as described in Methods. Prior studies have 
shown that gAd exhibits a variety of salutary effects in the vascula-
ture, including reduction of oxidative stress in cultured endothelial 
cells (16, 18, 21), and atheroprotective effects in the cardiovascular 
system of the mouse, as recently reviewed by our group (22).
As measured by intravital microscopy, treatment with gAd nor-
malized leukocyte rolling flux, leukocyte rolling velocity, and leu-
kocyte adhesion to the values found in control WT mice (Figures 1 
and 2). These data support the hypothesis that the vascular inflam-
mation observed in states of adiponectin deficiency is amenable to 
treatment with selected adiponectin isoforms, specifically gAd.
gAd treatment reverses TNF-α induced leukocyte-endothelium interactions 
in WT mice. TNF-α is a circulating cytokine that induces endothelial 
dysfunction characterized by downregulation of the eNOS/NO bio-
synthetic machinery (23–25) and upregulation of endothelial CAM 
expression (11). Interestingly, adiponectin has been reported to 
reverse some of the in vitro inflammatory signaling effects of TNF-α 
Figure 1
Leukocyte-endothelium interactions in mouse peri-intestinal venules are 
increased by endogenous adiponectin deficiency. (A) Leukocyte rolling 
flux in WT mice and Ad–/– mice before and after treatment with human 
recombinant gAd (25 μg, s.c., twice daily for 10 days). (B) Leukocyte 
adhesion values under the same experimental conditions. Data are 
expressed as the mean ± SEM. Numbers at the base of the bars indi-
cate the number of mice studied in each group. Pharmacologically active 
doses of gAd prevent abnormal leukocyte–endothelial cell interactions in 
the microcirculation in the face of chronic adiponectin deficiency.
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in cultured endothelial cells (6). Accordingly, we determined whether 
pharmacologically active doses of gAd could inhibit TNF-α–medi-
ated leukocyte-endothelium interactions in WT mice expressing 
physiological levels of adiponectin. Two-hour exposure of the mouse 
microcirculation to 1 μg/kg TNF-α given i.p. increased leukocyte 
rolling 3-fold (P < 0.01; Figure 3A) and leukocyte adhesion 6-fold 
(P < 0.01; Figure 3B). Treatment of mice with 2 consecutive doses 
of gAd (25 μg/mouse, s.c.), given 24 hours and repeated 2.5 hours 
before TNF-α administration, attenuated TNF-α–mediated leuko-
cyte rolling by 2-fold and leukocyte adhesion by 3-fold (P < 0.01; 
Figure 3). These data demonstrate that pharmacologically active doses 
of gAd dramatically protect the vasculature against cytokine-induced 
inflammation, even in the presence of endogenous adiponectin.
Endogenous adiponectin and gAd treatment regulates NO availability 
in the vascular wall. To test the hypothesis that the antiinflamma-
tory effect of adiponectin in the vasculature is accompanied by 
enhanced availability of eNO, we measured eNO release from the 
isolated mouse aorta. Adiponectin deficiency was associated with 
a 40% reduction in NO production compared with that of control 
WT mice (Table 2; P < 0.01 versus WT aorta). Similarly, 2 hours 
after i.p. injection of 1 μg/kg of TNF-α into WT mice, eNO pro-
duction in the aorta was reduced by 36% (Table 2; P < 0.01 versus 
control WT mice). Treatment of Ad–/– mice with gAd for 6 con-
secutive days restored eNO production significantly toward the 
level observed in WT mice (Table 2; P > 0.05 versus WT). The effect 
of TNF-α to suppress eNO generation was also blocked by 55% 
Figure 2
Endogenous adiponectin deficiency decreases leukocyte rolling velocity in the microcirculation. Panels illustrate rolling velocities in all experi-
mental groups of mice. Data are expressed as the mean and represent the total leukocyte rolling frequency calculated from 5 mice in each group. 
Treatment of Ad–/– mice with human recombinant gAd (25 μg, s.c., twice daily for 10 days) normalizes leukocyte rolling velocity (top, middle panel). 
Similar results were obtained following functional blockade of E-selectin with the mAb 9A9 in Ad–/– mice (2.1 mg/kg, i.v.; bottom, right panel).
Table 1
Main metabolic and hemodynamic parameters in all experimental groups of mice
Group  Blood glucose  MABP  Wall shear  Average venule  Body weight  wbc  
(n) (mg/dl) (mmHg) rate (s–1) diameter (μm) (g) (106)
WT (6) 131 ± 6 86 ± 4 1745 ± 214 31.7 ± 2.0 31 ± 1 6.0 ± 0.6
WT + TNF-α (7) 137 ± 4 90 ± 4 2129 ± 233 27.6 ± 1.7 26 ± 1 5.3 ± 0.5
WT + TNF-α + gAd (5) 119 ± 6 94 ± 4 2430 ± 411 29.3 ± 1.3 27 ± 1 5.7 ± 0.3
WT + l-NAME (7) 121 ± 3 91 ± 3 2749 ± 135 28.3 ± 0.8 28 ± 0 6.3 ± 1.2
WT + l-NAME + gAd (4) 111 ± 5 101 ± 3 2125 ± 90 27.3 ± 0.9 26 ± 1 5.1 ± 0.3
Ad+/– (6) 127 ± 5 87 ± 2 1830 ± 170 29.0 ± 1.8 28 ± 2 5.6 ± 0.6
Ad–/– (8) 137 ± 5 89 ± 4 2084 ± 170 25.8 ± 0.8 26 ± 1 5.4 ± 0.7
Ad–/– + gAd (6) 126 ± 6 75 ± 6 1624 ± 76 32.8 ± 1.6 26 ± 1 5.7 ± 0.5
Ad–/– + l-NAME + gAd (4) 107 ± 6 98 ± 3 2661 ± 175 32.5 ± 0.6 33 ± 2 6.3 ± 1.4
Ad–/– + IgG1 (6) 113 ± 4 92 ± 4 2234 ± 88 26.7 ± 0.3 29 ± 1 5.8 ± 0.5
Ad–/– + mAb 9A9 (6) 122 ± 7 94 ± 2 2453 ± 112 24.3 ± 0.5 28 ± 1 7.0 ± 0.9
MABP, mean arterial blood pressure.
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with prior treatment with a double dose of 25 μg gAd, given as 
described above. These data clearly demonstrate that pharmaco-
logically active doses of gAd increase NO bioavailability not only 
in states of adiponectin deficiency but also in the context of nor-
mal adiponectin levels when the cardiovascular system is exposed 
to elevated cytokine levels.
In vivo eNOS blockade suppresses the antiinflammatory action of gAd. 
To further substantiate the involvement of eNO availability in 
the vascular protective action of adiponectin, we blocked eNOS 
activity with the specific inhibitor Nω-nitro-l-arginine methyl ester 
(l-NAME). In agreement with previous publications (26, 27), 
superfusion of the mesenteric microcirculation with 1 mM 
l-NAME increased leukocyte adherence 5-fold (P < 0.01 versus 
control; Figure 4), thus producing an inflammatory signal com-
parable to that observed after injection of TNF-α (Figure 3). 
l-NAME–induced leukocyte adherence was not affected by systemic 
treatment of WT mice with recombinant gAd (Figure 4). Moreover, 
l-NAME superfusion abolished the inhibitory effect of gAd treat-
ment on leukocyte adhesion in Ad–/– mice (Figure 4). These results 
demonstrate that functional eNOS activity is integrally involved in 
the antiinflammatory actions of gAd in the vasculature in vivo.
Endogenous adiponectin and gAd treatment regulate expression of 
endothelial CAMs: functional implications. To identify the underlying 
molecular mechanism(s) responsible for the increased leukocyte-
endothelium interactions observed in states of adiponectin defi-
ciency, we used immunohistochemistry to measure expression 
levels of E-selectin and VCAM-1, 2 proinflammatory endothelial 
CAMs known to regulate leukocyte halting and leukocyte firm 
adhesion in the microcirculation. The percentage of venules 
staining positively for E-selectin in ileal sections from WT mice 
was consistently low (Figure 5). However, Ad–/– and Ad+/– mice 
exhibited a significantly increased expression of E-selectin as 
quantified by the percentage of positively staining venules. 
Increased E-selectin expression on the venular endothelium of 
Ad–/– mice was attenuated by gAd treatment (Figure 5). Similarly, 
few ileal venules stained positive for VCAM-1 in WT control mice 
(Figure 5). The number of ileal venules staining positive for 
VCAM-1 expression increased in Ad+/– mice and Ad–/– mice. 
Furthermore, treatment with gAd attenuated the expression of 
VCAM-1 in ileal venules of Ad–/– mice (Figure 5).
Previous studies have implicated E-selectin in both leukocyte 
rolling and leukocyte adhesion (28, 29). Accordingly, we sought to 
investigate the contribution of E-selectin to leukocyte adhesion in 
our Ad–/– mouse model by acutely blocking E-selectin function with 
a bolus injection of the E-selectin mAb 9A9 to Ad–/– mice. Following 
systemic administration of the mAb 9A9, leukocyte adhesion in Ad–/– 
mice was drastically reduced (Figure 6A), demonstrating that 
E-selectin is largely responsible for leukocyte adhesion in states of 
adiponectin deficiency. Leukocyte rolling values in Ad–/– were slight-
ly increased following administration of mAb 9A9 although they 
failed to reach statistical significance (Figure 6B). Nonetheless, treat-
ment with mAb 9A9 significantly increased leukocyte rolling veloc-
ity in Ad–/– mice from 19.3 ± 1.4 μm/s to 35.6 ± 2.9 μm/s (Figure 2). 
Together, these data strongly correlate with the functional changes 
in leukocyte-endothelium interactions shown in Figures 1 and 2. 
They also emphasize the role of E-selectin in the vascular inflam-
mation associated with adiponectin-deficient states.
Discussion
This study was undertaken to investigate the early mechanisms 
of endothelial dysfunction associated with systemic adiponectin 
deficiency, an area of growing interest given the high incidence of 
vascular disease in metabolic states associated with obesity and 
Figure 3
Pharmacologically active doses of gAd reverse TNF-α–induced leuko-
cyte-endothelium interactions in WT mice. As shown in A and B, 1 μg/kg 
TNF-α given 2 hours before the experiment increases leukocyte rolling 
flux and leukocyte adhesion, respectively, in the microcirculation of WT 
mice. Two 25 μg doses of gAd given 24 hours and 2.5 hours before 
intravital microscopy significantly attenuates TNF-α–induced leukocyte 
rolling and adhesion, confirming the potent antiinflammatory action of 
pharmacologic doses of gAd also in mice expressing physiologic adi-
ponectin levels. Data are expressed as the mean ± SEM. Numbers at 
the base of the bars indicate the number of mice studied in each group.
Table 2
Release of NO
Group (n) NO (pmol/mg tissue)
WT (3) 142.4 ± 6.3
WT + TNF-α (3) 90.7 ± 7.8A
WT + gAd + TNF-α (3) 119.2 ± 6.9B
Ad–/– (3) 84.8 ± 4.7A
Ad–/– + gAd (3) 120.2 ± 7.9C
NO release was measured in isolated mouse aortic rings obtained from 
WT or Ad–/– mice given 0.9% saline or TNF-α i.p. (1 μg/kg, injected 2 
hours before isolation of aortas). In the gAd-treated WT mouse group, mice 
were injected s.c. with 25 μg of gAd/mouse 24 hours before and again 2.5 
hours before isolation of aortic rings. In the gAd-treated Ad–/– mouse group, 
mice were injected s.c. with 25 μg of gAd/mouse given twice a day for 6 
consecutive days. All values were obtained from 3 mice in each group. 
Three aortic segments were studied in each mouse. AP < 0.01 versus WT;  
BP < 0.05 versus WT + TNF-α; CP < 0.05 versus Ad–/–.
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adipocyte dysfunction. We believe our results are the first in vivo 
demonstration that global adiponectin deficiency increases leuko-
cyte-endothelial cell interactions via reduced availability of eNO at 
the vascular wall and upregulation of endothelial CAMs that are rel-
evant to vascular inflammation and atherosclerosis. We also provide 
evidence that systemic administration of pharmacologically active 
doses of the recombinant gAd fragment alone reverts the endothelial 
dysfunction associated with adiponectin deficiency and attenuates 
cytokine-induced vascular inflammation in WT mice expressing 
physiologic concentrations of adiponectin in the blood.
Recruitment of circulating leukocytes is important in 
the pathophysiology of macrovascular (30) and micro-
vascular diseases (17). The healthy endothelium does not 
bind circulating leukocytes under normal conditions. In 
the early stages of endothelial dysfunction, there is an 
increase in endothelial cell expression of various adhesion 
molecules on the luminal surface, including selectins and 
CAMs, all of which act as receptors for glycoconjugates 
and integrins present on the circulating leukocytes (31). 
Trafficking leukocytes are known to be detrimental to 
the vessel wall and tissues (32). Traditionally, it has been 
believed that prolonged exposure of the vascular endo-
thelium to elevated circulating levels of metabolites or 
inflammatory mediators, such as glucose, free fatty acids, 
oxidized LDL, and cytokines, causes endothelial dysfunc-
tion by perturbing endothelial cell homeostasis. Recent 
research, however, has emphasized the role of adipose tis-
sue and the deranged secretory properties of adipocytes 
in obesity as major causes of endothelial dysfunction (2). 
Dysfunction of adipose tissue, such as that occurring in 
obesity and insulin resistance, is characterized by system-
ic activation of inflammatory signals (33). Many of these 
signals arise directly or indirectly from secretory products 
of white adipocytes and actively contribute to the circu-
lating milieu that induces vascular dysfunction (34, 35).
The reduction of circulating adiponectin levels in obe-
sity and insulin resistance (4, 36) is of particular interest 
in view of the fact that low adiponectin levels are associ-
ated with endothelial dysfunction in humans (14, 37, 38). 
This observation has been confirmed in several relevant 
animal models of disease in which reduced blood levels 
of adiponectin have been proven to exacerbate vascular 
injury (8, 39, 40). In vivo studies have also proven that 
adiponectin overexpression protects ApoE-deficient mice from 
atherosclerosis (41). Evidence has been also published to show 
that circulating adiponectin binds to the vascular wall of cath-
eter-injured vessels, although the functional implications of this 
observation for vascular homeostasis are not known (42). More 
mechanistic studies in vitro have demonstrated that this adipo-
kine is provided with antiinflammatory properties against oxi-
dative stress and the action of cytokines (18, 43), suggesting that 
inhibition of inflammatory signals is the fundamental mechanism 
of the vascular protective actions of adiponectin in vivo.
Our data demonstrating that adiponectin deficiency increases 
leukocyte rolling and leukocyte adhesion help to explain a key 
mechanism by which loss of physiologic levels of adiponectin 
causes a generalized state of chronic vascular inflammation in vivo. 
Figure 4
Functional eNOS activity is necessary for the antiinflammatory 
effect of gAd. Superfusion of the mouse mesenteric microcirculation 
with the eNOS inhibitor l-NAME increases leukocyte adhesion in 
WT mice (white bars). Two 25 μg doses of gAd given 24 hours and 
2.5 hours before intravital microscopy failed to prevent leukocyte 
adhesion in response to l-NAME. Moreover, attenuation of leuko-
cyte adhesion by administration of gAd (25 μg/twice daily for 6 con-
secutive days) to Ad–/– mice is acutely hampered by superfusion of 
the microcirculation with l-NAME (black bars). Data are expressed 
as the mean ± SEM. Numbers at the base of the bars indicate the 
number of mice studied in each group.
Figure 5
Adiponectin deficiency increases E-selectin and VCAM-1 expression levels in 
the vascular endothelium of the mouse microcirculation. Representative sections 
of ileal venules (Vs) staining positive for E-selectin are shown in the top 3 photo-
micrographs. E-selectin staining in all experimental groups of mice was detected 
by avidin/biotin immunoperoxidase technique seen as brown reaction product 
(arrows). Original magnification, ×500. Bottom graphs show quantification of the 
percentage of venules staining positive for E-selectin (left) and VCAM-1 (right). 
Values are mean ± SEM. Numbers at base of bars indicate the number of mice 
studied in each group. Five tissue sections were studied in each mouse, and 
50 venules were analyzed per section.
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Specific adhesion molecules expressed on endothelial cells orches-
trate the recruitment of circulating leukocytes under physiologic 
and pathophysiologic conditions. We found evidence of increased 
leukocyte rolling flux associated with reduced leukocyte rolling 
velocities and increased leukocyte adhesion (Figures 1 and 2) in 
the microcirculation of Ad–/– mice. Accordingly, we measured the 
expression of E-selectin and VCAM-1 in the Ad–/– vascular endo-
thelium and found evidence of increased E-selectin and VCAM-1 
expression in Ad–/– mice. Upregulation of E-selectin reduces roll-
ing velocities of leukocytes (20) and participates in the conver-
sion of rolling to firm adhesion, as demonstrated by the fact that 
E-selectin–deficient mice have a reduced number of firmly adher-
ent leukocytes in response to local chemoattractant (28) or 
cytokine stimulation (29). To determine whether the increased 
adhesion of leukocytes seen in Ad–/– mice is functionally dependent 
on E-selectin, we blocked E-selectin function in vivo with a mAb. 
Consistent with the previous studies cited above, we found that 
blockade of E-selectin function in Ad–/– acutely increased leuko-
cyte rolling velocity and inhibited leukocyte adhesion in the face of 
adiponectin deficiency. Taken together, these data highlight a role 
for E-selectin in the endothelial dysfunction and vascular inflam-
mation associated with loss of physiologic levels of adiponectin.
The type I transmembrane glycoprotein VCAM-1 was also found 
to be upregulated in the vascular endothelium of mice deficient in 
adiponectin. VCAM-1 expression is very low or absent under physi-
ologic conditions, and its expression levels can be rapidly induced 
by cytokines, such as TNF-α (31). VCAM-1 has been implicated 
in the process of atherogenesis and plaque formation both in the 
mouse and in humans (44, 45). Relevant to our study, VCAM-1 
mediates firm adhesion of leukocytes by functioning as a counter-
receptor to leukocyte integrins (46). Our functional studies dem-
onstrated that leukocyte adhesion in the microcirculation of Ad–/– 
mice is largely dependent on E-selectin. Thus, future research must 
be undertaken to clarify whether VCAM-1 also plays a significant 
role in the vascular inflammation associated with adiponectin 
deficiency, since we clearly found evidence of increased VCAM-1 
expression in this condition (Figure 5).
In addition to upregulating CAMs, the dysfunctional endotheli-
um experiences loss of eNO (11). Loss of eNO contributes to hyper-
tension and several concomitant alterations, including increased 
expression of endothelial adhesion molecules that underlie the 
early processes of atherosclerosis (13–15). Overall, there is a con-
sensus in the literature that the antiinflammatory action of eNO 
is largely based on its inhibitory effect on leukocyte-endothelium 
interactions. At the molecular level, NO suppresses leukocyte-
endothelium interactions by inhibiting exocytosis of Weibel-Pal-
ade bodies and modulating the activity of NF-κB (11, 47). Inter-
estingly, induction of E-selectin by cytokines occurs exclusively at 
the transcriptional level and requires proteasome-dependent acti-
vation of NF-κB for maximal expression (48). As with E-selectin, 
activation of the NF-κB signal transduction pathway is essential 
for cytokine-induced VCAM-1 expression (49). Adiponectin has 
been shown to inhibit NF-κB activation in endothelial cells (6). 
Here, we report that loss of circulating levels of adiponectin is 
associated with reduced bioavailability of eNO. Thus, our results 
clearly show that the presence of adiponectin in the mouse circu-
lation contributes to maintaining the endogenous production of 
eNO. Consistent with these results, our laboratory and others have 
reported that adiponectin enhances NO production in cultured 
endothelial cells (14–16).
Directly relevant to the clinical application of these data is our 
finding that pharmacologically active doses of gAd almost com-
pletely reverse the increase in leukocyte-endothelium interactions 
observed in both Ad–/– mouse vasculature and WT mouse vascu-
lature acutely inflamed with TNF-α. Several adiponectin multi-
meric isoforms, in addition to full-length adiponectin, have been 
isolated in the blood and tissues of humans and laboratory animals 
(1, 2). Recent research has emphasized a role for the gAd fragment 
that is now known to have metabolic as well as vascular protective 
functions (40, 50). Indeed it has been hypothesized that gAd may 
circulate in the blood of humans at a very low concentration or 
processed from the full-length protein at a local site (50), although 
no definitive evidence has been provided. This fragment of adipo-
nectin has also been hypothesized to be a pharmacologically potent 
form of adiponectin that may be generated by a proteolytic cleavage 
step in vivo, although work in this area is ongoing (2, 50). In sup-
port of a potential therapeutic role for gAd, however, our results 
show that gAd treatment affords significant pharmacological pro-
tection against vascular inflammation at concentrations well below 
those of the physiological levels of circulating full-length adiponec-
tin complexes. At the molecular level, we found evidence that gAd 
attenuates expression levels of E-selectin and VCAM-1 in Ad–/– mice, 
a result that agrees with our functional observation demonstrating 
reduced leukocyte adhesion following gAd therapy in the mouse. 
Figure 6
E-selectin supports leukocyte adhesion in the Ad–/– microcircula-
tion. (A) Leukocyte adhesion in Ad–/– mice before and after in vivo 
blockade of E-selectin with the E-selectin function–blocking mAb 9A9 
(2.1 mg/kg). Leukocyte adhesion was not affected by systemic admin-
istration of control IgG1 (2.1 mg/kg). Leukocyte rolling values in Ad–/– 
were slightly increased following administration of mAb 9A9, although 
they failed to reach statistical significance (B). Values represent the 
mean ± SEM of rolling or adherent leukocytes. Numbers at the base of 
the bars indicate the number of mice studied for each group.
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Mechanistically, we also found evidence that gAd increases avail-
ability of eNO in Ad–/– mice and that blockade of eNOS enzyme 
activity with l-NAME abolishes the inhibitory effect of adiponectin 
on leukocyte endothelium interactions. Indeed, in TNF-α–treated 
mice, gAd increased aortic eNO levels by approximately 50% while 
leukocyte–endothelial cell interaction in the mesenteric microcir-
culation was almost completely blocked. The apparent discrepancy 
between the antiinflammatory effect of gAd in the microcircula-
tion and its eNO augmenting action in the aorta could be due in 
part to different sensitivities of microvascular and macrovascular 
endothelia to the NO potentiating action of gAd. Future studies 
on gAd receptor distribution and activity in different vasculatures 
are needed to fully understand the impact of adiponectin in the 
homeostasis of individual vascular beds. Taken together, these data 
clearly demonstrate that an eNO-related mechanism is involved in 
the vascular protective action of adiponectin.
The antiinflammatory action of gAd was also confirmed in the 
WT mouse vasculature inflamed with a clinically relevant cytokine 
such as TNF-α. In fact, TNF-α/NF-κB signaling is well recog-
nized as a strong regulator of inflammation in the vasculature 
in humans (51). Relevant to this view, cytokines such as TNF-α 
are closely linked to the endothelial production of ROS (superox-
ide and H2O2), a central component of the inflammatory milieu 
that contributes to atherogenesis in some pathologic conditions 
(52–54). ROS can quickly quench NO, a process that results in 
the formation of peroxynitrite, which has also been postulated to 
alter the catalytic activity of eNOS, diverting its synthesis from 
NO toward increased superoxide production (55). In addition, 
TNF-α directly downregulates basal and insulin-stimulated eNOs 
expression (56). Recent work has shown in vitro that gAd stimula-
tion of NO generation is associated with enhanced eNOS complex 
formation with HSP90 (57). In agreement with this view, a recent 
study in vitro has demonstrated that full-length adiponectin sup-
presses TNF-α–induced adhesion molecule expression in cultured 
endothelial cells (18). We have also previously shown suppression 
of ROS by gAd in cultured endothelial cells treated with oxidized 
LDL or high glucose (16, 28). However, additional studies are 
needed to further elucidate the potential pharmacological effects 
of various adiponectin isoforms, including multimers and adipo-
nectin fragments such as gAd in vascular inflammation.
In summary, our data demonstrate a clear role for physiolog-
ic levels of adiponectin in the regulation of eNO bioavailability 
and leukocyte-endothelium interactions in vivo. They also dem-
onstrate that the abnormal endothelial dysfunction occurring in 
pathologic conditions associated with adiponectin deficiency is 
amenable to gAd pharmacologic treatment.
Methods
Animal models and study protocols. This study was performed in accordance 
with NIH guidelines for the use of experimental animals. The Institutional 
Animal Care and Use Committee of Thomas Jefferson University approved 
all of the animal protocols. WT C57BL/6J mice were purchased from 
Charles River Laboratories. Ad–/– mice, extensively backcrossed to C57BL/6J 
controls, were generated and characterized as reported (19). Ad+/– mice 
were obtained by backcrossing Ad–/– with WT mice. In all reported experi-
ments, male mice were studied at age 12–17 weeks. The role of adiponectin 
deficiency and gAd therapy on leukocyte-endothelium interactions was 
studied in the following 4 groups of mice: (a) WT mice given saline; (b) 
Ad–/– mice given saline; (c) Ad+/– mice given saline; and (d) Ad–/– mice given 
gAd of 25 μg twice daily for 10 consecutive days. The inhibitory action of 
gAd (25 μg given 24 hours and repeated 2.5 hours before experiment) on 
leukocyte-endothelium interactions was also studied in WT mice injected 
with 1 μg/kg TNF-α i.p. 2 hours before experiment. In parallel experi-
ments, the microcirculation of WT and Ad–/– mice was superfused with 
1 mM l-NAME to study the role of eNOS activity in the mechanism by 
which gAd inhibits leukocyte-endothelium interactions. l-NAME has been 
used before to induce leukocyte-endothelium interactions in the microcir-
culation (12). In additional studies, Ad–/– mice were given 2 mg/kg i.v. of the 
E-selectin function–blocking antibody 9A9 or control IgG1 to determine 
the contribution of E-selectin to the increased leukocyte adhesion seen in 
states of adiponectin deficiency. Previous studies have demonstrated that 
mAb 9A9 efficiently blocks E-selectin function in the mouse (28, 58). In 
all experiments, pharmacologically active doses of gAd were delivered to 
the mouse via s.c. injection. Previous studies have shown that adiponectin 
injected s.c. is absorbed into the systemic circulation (59).
Fluorescence intravital microscopy of mouse peri-intestinal venules. Mice were 
anesthetized by i.p. injection of 70 mg/kg sodium pentobarbital. Addition-
al sodium pentobarbital was administered i.v. as needed during the intravi-
tal microscopy observation time. Polyethylene catheters were inserted into 
the left carotid artery to monitor mean arterial blood pressure and into the 
right jugular vein for administration of saline, pentobarbital, rhodamine, 
and antibodies. A loop of ileal mesentery was exteriorized through a mid-
line incision in the abdominal wall and placed in a temperature-controlled, 
fluid-filled Plexiglas chamber (developed in our laboratory) for observation 
of the peri-intestinal microcirculation by intravital microscopy. The ileum 
and mesenteric tissue were superfused throughout the experiment with a 
modified Krebs-Henseleit (K-H) buffer warmed to 37°C and bubbled with 
95% N2/5% CO2. Centerline red blood cell velocity (Vrbc) was monitored in 
bright field using an optical Doppler velocimeter (Department of Systems 
Biology and Translational Medicine, Texas A&M University System Health 
Science Center). Vrbc and venular diameter (D) were used to calculate the 
venular wall shear rate (γ) with the following formula: γ = 4.9×8(Vmean/D), 
where mean velocity of red blood cells (Vmean) equals Vrbc/1.6 (60).
Postcapillary venules (20- to 40-μm diameter) were observed under fluo-
rescence microscopy, using a previously described intravital microscopy 
unit (61). Leukocytes were fluorescently labeled in vivo by injection of 
0.3 mg/kg Rhodamine 6G (Sigma-Aldrich) injected via the right jugular vein. 
Rhodamine 6G–labeled leukocytes were monitored at a final magnification 
of ×400 using appropriate filter sets. The microscopic images were record-
ed on an IBM computer equipped with Image-Pro software (version 4.5; 
MediaCybernetics). Leukocytes were classified according to the quality or 
duration of their interaction with the venular wall as rolling or adherent. 
The leukocyte rolling flux was defined as the total number of leukocytes 
crossing the 100-μm venular segment in 60 seconds at a velocity that was 
significantly lower than the centerline velocity. Leukocyte rolling veloc-
ity was determined by measuring the time required for a leukocyte to roll 
along a 100-μm length of venule. Leukocytes that were stationary for more 
than 30 seconds were defined as adherent. Leukocyte adhesion is expressed 
as the number of cells/100 μm of venular length. For experiments with 
l-NAME, mice were allowed to stabilize for 30 minutes following surgery. 
Following stabilization, a 20- to 40-μm–diameter postcapillary venule was 
chosen for observation. A baseline recording was made to establish basal 
values for leukocyte rolling and adherence. The mesentery was then super-
fused with 1 mM l-NAME dissolved in K-H solution for 60 minutes. Video 
recordings were made at 0, 15, 30, 45, and 60 minutes after initiation of 
superfusion for quantification of leukocyte rolling and adherence.
Adhesion of cultured monocytes to the mouse aorta in vitro. For these studies, 
we used an in vitro adhesion assay previously described (62). In brief, the 
thoracic aorta was isolated from donor WT and Ad–/– mice euthanized with 
an overdose of sodium pentobarbital (150 mg/kg) injected i.p. The aorta 
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was quickly removed and placed in cold, oxygenated PBS. After carefully 
removing the adventitia, aortas were cut to 4-mm segments. The segments 
were then carefully opened longitudinally and placed into culture dishes 
containing 1 ml K-H solution with their luminal surfaces facing up.
Human monocytic cells (THP-1) were cultured in RPMI-16 (+2 mM 
glutamine + 0.05 mM 2 mercaptoethanol + 10% FBS; Invitrogen). Before 
adhesion assay, THP-1 cells were fluorescently labeled using Zynaxis PKH2 
staining kit (Zynaxis Cell Sciences Inc.) according to a previously described 
method (63). All steps were performed at 25°C. A suspension of THP-1 
monocytic cells was incubated with 4 μM PKH-2GL for a labeling period of 
5 minutes. The labeling was stopped by adding PBS containing 10% FCS. 
Monocytic cells were incubated with 100 nM formyl-Met-Leu-Phe for 5 
minutes. Activated monocytic cells were then incubated with the aortic seg-
ments at a concentration of 105 cells/well for 20 minutes at room tempera-
ture in an orbital shaker platform (Scienceware; Bel-Art Products). The aor-
tic segments were then removed, gently washed in fresh K-H solution, and 
placed lumen side up on a microscope slide. The aortic tissue was covered 
with a drop of immersion oil followed by a glass coverslip. The number of 
monocytic cells adhering to the endothelial surface in 4 separate microscop-
ic fields was counted under epifluorescent microscopy at a magnification of 
×200. Results are expressed as total number of cells/microscopic field.
Measurement of NO production in isolated aorta. Basal level of NO was 
measured in WT mice, WT mice injected with TNF-α, and Ad–/– mice. 
The effect of gAd on basal NO levels was also studied. Mouse thoracic 
aorta rings, freshly isolated from donor mice, as described above, were 
used as the source of primary endothelial cells for measurement of NO 
production. The thoracic aortas were cut into 4-mm rings, which were 
then opened and fixed by small pins with the endothelial surface facing 
upwards in 24-well culture dishes containing 1 ml of prewarmed K-H 
solution. After equilibration at 37°C, NO released into the K-H solution 
was measured as previously reported (64). Briefly, a polarographic NO 
electrode internally shielded to minimize external electrical interference 
was connected to NO meter (Apollo 4000; World Precision Instruments). 
Calibration of the NO electrode was performed daily prior to each experi-
mental protocol as previously described (65). Standard calibration curve 
was obtained by graded final concentrations of KNO2 from 0 to 500 nM 
into a calibration solution containing 0.1 M potassium iodide and 0.1 M 
H2SO4. Release of NO was expressed as pmol/mg of dry tissue.
Immunohistochemistry. Following intravital microscopy experiments, the 
thorax was carefully opened, avoiding excessive bleeding. The vasculature 
was then flushed to remove red blood cells by carefully injecting saline in 
the left ventricle while the right ventricle was cut open for drainage (66). 
Once the vasculature was free of red blood cells, mice were perfused with ice-
cold 4% paraformaldehyde for 3–5 minutes. Sections of ileum (3–4 cm) were 
then collected and placed in 4% paraformaldehyde for 2 hours on ice. The 
tissue was then cut into rings, dehydrated by using graded acetone washes, 
and embedded in plastic (Immunobed; Polysciences Inc.). Sections (5-μm 
thick) were cut and transferred to Vectabond-coated slides (Vector Labora-
tories). Immunohistochemical localization of E-selectin and VCAM-1 was 
accomplished by using the avidin/ biotin immunoperoxidase technique 
(VECTASTAIN ABC Reagent: Vector Laboratories) and with mAbs against 
either E-selectin or VCAM-1, as described previously (67). Briefly, blocking 
serum (horse) was applied to the tissue for 30 minutes to reduce nonspecific 
binding, and then the tissue sections were incubated with the primary anti-
body at a dilution of 1/100 for 24 hours. The tissue was then incubated with 
the biotinylated secondary antibody, and peroxidase staining was carried out 
using 3,3′-diaminobenzidine. Control preparations involved omission of the 
primary antibody or omission of the secondary antibody. A total of 5 to 6 
sections were studied from each mouse. Fifty venules were then analyzed per 
tissue section, and the percentage of positive staining was determined.
Plasma measurements. Endogenous total adiponectin levels and levels 
of the injected gAd in mouse serum were determined using mouse -and 
human-specific immunoassay kits from R&D Systems. A drop of blood 
was collected through tail vein puncture to measure blood glucose levels 
using an Accu-Chek handheld glucose meter (Roche Diagnostics).
Reagents and solutions. Recombinant gAd was purchased from PeproTech. 
Monoclonal antibodies to mouse E-selectin (10E9.6) and VCAM-1 
(MR106) for immunohistochemistry were purchased from BD Biosci-
ences. Isotype control for E-selectin antibody, rat IgG1, was purchased 
from BD Biosciences — Pharmingen. Human recombinant TNF-α was 
purchased from Sigma-Aldrich.
Statistics. All data are presented as mean ± SEM for the number of deter-
minations shown in the figure or table. All data on leukocyte rolling and 
adherence as well as on mean arterial blood pressure, shear rates, and NO 
production levels were compared by ANOVA with post hoc analysis by 
Neuman-Keuls corrected t test. P values of 0.05 or less were considered 
statistically significant.
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